Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bristol-Myers Squibb Company before investing.

In this article, we go over a few key elements for understanding Bristol-Myers Squibb Company’s stock price such as:

• Bristol-Myers Squibb Company’s current stock price and volume
• Why Bristol-Myers Squibb Company’s stock price changed recently
• Upgrades and downgrades for BMY from analysts
• BMY’s stock price momentum as measured by its relative strength

About Bristol-Myers Squibb Company (BMY)

Before we jump into Bristol-Myers Squibb Company’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Want to learn more about Bristol-Myers Squibb Company’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Bristol-Myers Squibb Company’s stock price was $65.310.

Bristol-Myers Squibb Company is up 0.69% from its previous closing price of $64.860.

During the last market session, Bristol-Myers Squibb Company’s stock traded between $63.530 and $65.660. Currently, there are approximately 2,038.00 million shares outstanding for Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company’s price-earnings (P/E) ratio is currently at 18.2, which is low compared to the Pharmaceuticals industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Bristol-Myers Squibb Company Stock Price History

Bristol-Myers Squibb Company’s (BMY) price is currently up 13.35% so far this month.

During the month of July, Bristol-Myers Squibb Company’s stock price has reached a high of $65.660 and a low of $56.300.

Over the last year, Bristol-Myers Squibb Company has hit prices as high as $65.560 and as low as $42.520. Year to date, Bristol-Myers Squibb Company’s stock is up 21.08%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bristol-Myers Squibb Company Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded Bristol-Myers Squibb Company’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Bristol-Myers Squibb Company’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bristol-Myers Squibb Company’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Bristol-Myers Squibb Company’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bristol-Myers Squibb Company (BMY) by visiting AAII Stock Evaluator.

Relative Price Strength of Bristol-Myers Squibb Company

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Bristol-Myers Squibb Company has a weighted four-quarter relative price strength of 5.35%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Bristol-Myers Squibb Company is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bristol-Myers Squibb Company Stock Price: Bottom Line

As of July 31, 2026, Bristol-Myers Squibb Company’s stock price is $65.310, which is up 0.69% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bristol-Myers Squibb Company stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.